TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36095141

Group type: EXPERIMENTAL
Intervention: Equol producers (EPs)
Number of subjects: 2958

Group type: EXPERIMENTAL
Intervention: Fecal acylcarnitine metabolites
Number of subjects: 2958

Group type: EXPERIMENTAL
Intervention: Path analyses
Number of subjects: 2958
Study: 36095315

Group type: EXPERIMENTAL
Intervention: Adrenal computed tomography screening for adrenal tumors
Number of subjects: 25356

Group type: EXPERIMENTAL
Intervention: Adrenocortical adenoma
Number of subjects: 25356

Group type: EXPERIMENTAL
Intervention: Endocrine testing for adenomas
Number of subjects: 25356

Group type: EXPERIMENTAL
Intervention: Age-related prevalence of adrenal tumors
Number of subjects: 25356
Study: 36095841

Group type: EXPERIMENTAL
Intervention: Itacitinib 200 mg/d for 28 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: SCS treatment
Number of subjects: 70
Study: 36095849

Group type: EXPERIMENTAL
Intervention: Cilta-cel infusion after lymphodepletion
Number of subjects: 20
Study: 36096442

Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily (after 7-day 90-mg lead-in)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily (after 7-day 90-mg lead-in) in patients with ctDNA-detectable baseline ALK fusion (n=64)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily (after 7-day 90-mg lead-in) in patients who progressed on alectinib (n=86)
Number of subjects: 103
Study: 36096532

Group type: EXPERIMENTAL
Intervention: BND-22 (ILT2-blocking antibody)
Number of subjects: 0
Study: 36096779

Group type: EXPERIMENTAL
Intervention: Communities with both MWH and SILC (CG3)
Number of subjects: 4711

Group type: COMPARATOR
Intervention: Communities with only MWH (CG2)
Number of subjects: 4711

Group type: COMPARATOR
Intervention: Communities with neither MWH nor SILC (CG1)
Number of subjects: 4711
Study: 36096801

Group type: EXPERIMENTAL
Intervention: Severe COVID-19 pneumonia patients
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Radiological assessment at 12 months
Number of subjects: 284
Study: 36096816

Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discharged directly home
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All participants (pre-surgery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All participants (3-months post-surgery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All participants (12-months post-surgery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All participants (36-months post-surgery)
Number of subjects: 0
Study: 36096873

Group type: EXPERIMENTAL
Intervention: HIIT+RT
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study: 36096940

Group type: EXPERIMENTAL
Intervention: Group Metacognitive Therapy (MCT), up to eight sessions delivered by a CAMHS mental health practitioner
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care in CAMHS (individual or group-based therapy)
Number of subjects: 100
Study: 36096944

Group type: EXPERIMENTAL
Intervention: Pregnant group (hypocapnic alkalosis)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pregnant group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy, non-pregnant women)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 36097216

Group type: EXPERIMENTAL
Intervention: neoadjuvant atezolizumab monotherapy
Number of subjects: 181
Study: 36097345

Group type: EXPERIMENTAL
Intervention: GSK1795091 (modified formulation)
Number of subjects: 54

Group type: COMPARATOR
Intervention: GSK1795091 (original formulation)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: GSK1795091 (both formulations)
Number of subjects: 54
Study: 36097353

Group type: EXPERIMENTAL
Intervention: EEG and fMRI
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Combined EEG and fMRI features
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Machine-learning algorithms (SVM and Random Forest)
Number of subjects: 87
Study: 36097602

Group type: EXPERIMENTAL
Intervention: Asfotase alfa (enzyme replacement therapy)
Number of subjects: 6
Study: 36097728

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 15785
Study: 36097833

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 299
Study: 36097844

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine (fourth dose)
Number of subjects: 324
Study: 36098121

Group type: EXPERIMENTAL
Intervention: Treated HIV infection
Number of subjects: 981

Group type: COMPARATOR
Intervention: HIV-negative participants
Number of subjects: 981
Study: 36098319

Group type: EXPERIMENTAL
Intervention: Inoculation with RSV Memphis-37 in older adults (aged 60-75 years)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Inoculation with RSV Memphis-37 in younger adults (aged 18-55 years)
Number of subjects: 33
Study: 36098320

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (nivolumab 240 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nivolumab alone (240 mg every 2 weeks)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 66
Study: 36098367

Group type: EXPERIMENTAL
Intervention: Varlitinib + Capecitabine (VC)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Lapatinib + Capecitabine (LC)
Number of subjects: 77
Study: 36098470

Group type: EXPERIMENTAL
Intervention: SHR3680 coadministered with repaglinide
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: SHR3680 coadministered with bupropion
Number of subjects: 18
Study: 36098502

Group type: EXPERIMENTAL
Intervention: Rapid sequencing (<48 hr)
Number of subjects: 2170

Group type: COMPARATOR
Intervention: Longer-turnaround sequencing (5-10 days)
Number of subjects: 2170
Study: 36098877

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg or 200 mg
Number of subjects: 2
Study: 36098990

Group type: EXPERIMENTAL
Intervention: Smartphone monitoring app and wearables for 6 weeks
Number of subjects: 58
Study: 36099009

Group type: EXPERIMENTAL
Intervention: NeuroSuitUp platform (including visual motor imagery training, robotic arms controlled by BCI, wearable robotics jacket and gloves, serious game application, augmented reality module)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NeuroSuitUp platform
Number of subjects: 0
Study: 36099010

Group type: EXPERIMENTAL
Intervention: Single-patch 12-lead ECG (SP-ECG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional ECG (C-ECG)
Number of subjects: 36
Study: 36099049

Group type: EXPERIMENTAL
Intervention: Immune effector dysfunction (IED) scores derived from gene expression profiling platforms.
Number of subjects: 1896

Group type: EXPERIMENTAL
Intervention: Senescent-like bone marrow CD8+ T cells.
Number of subjects: 1896

Group type: EXPERIMENTAL
Intervention: Identification of ICB-unresponsive tumor microenvironment using IED expression signatures.
Number of subjects: 1896
Study: 36099312

Group type: EXPERIMENTAL
Intervention: Pf-Pv co-infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All parasites co-infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gametocytes co-infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pf co-infection with Pm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple infections (Pf-Pv-Pm)
Number of subjects: 0
Study: 36099505

Group type: EXPERIMENTAL
Intervention: Impact of Events Scale-revised (IES-R)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Centre for Epidemiological Studies Depression Scale (CES-D)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: EQ-5D-5L (health-related quality of life)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Gender and age analysis
Number of subjects: 196
Study: 36099671

Group type: EXPERIMENTAL
Intervention: Chemoradiation (CRT) for early PET non-responders (P-NR) after induction CTX
Number of subjects: 75

Group type: COMPARATOR
Intervention: Induction chemotherapy (CTX)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: PET response after induction CTX
Number of subjects: 75
Study: 36100197

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: EHR methodology and computable phenotype
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: EHR-based tools
Number of subjects: 6
Study: 36100207

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) adherence to guidelines
Number of subjects: 3562

Group type: EXPERIMENTAL
Intervention: Eating Behavior (EB) adherence to guidelines
Number of subjects: 3562
Study: 36100310

Group type: EXPERIMENTAL
Intervention: C-CAR088 (novel humanized anti-BCMA CAR T-cell therapy)
Number of subjects: 31
Study: 36100318

Group type: EXPERIMENTAL
Intervention: Cocoa (dark chocolate) 30 g/day for 1 week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (Clopidogrel without cocoa)
Number of subjects: 20
Study: 36100355

Group type: EXPERIMENTAL
Intervention: Intranasal nalbuphine (0.1 mg/kg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Intravenous nalbuphine (0.05 mg/kg)
Number of subjects: 52
Study: 36100698

Group type: EXPERIMENTAL
Intervention: Testosterone and cortisol stimulation in vitro
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: MDA-PCa-250 xenograft in intact mice
Number of subjects: 3

Group type: COMPARATOR
Intervention: MDA-PCa-250 xenograft in castrated mice
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Adrenalectomy during castration-resistant oligometastatic disease
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Somatic DNA whole exome sequencing (WES)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry (IHC)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: RNA-Seq
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Steroid quantitation
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Stable isotope tracing of organoid from MDA-PCa-250
Number of subjects: 3
Study: 36100880

Group type: EXPERIMENTAL
Intervention: Better Together Physician Coaching (6-month, self-paced, online, asynchronous coaching program)
Number of subjects: 17
Study: 36100966

Group type: COMPARATOR
Intervention: Maize alone (labeled 54FeSO4)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Maize + NC T. molitor (intrinsically labeled 57Fe)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Maize + LC T. molitor (dechitinized intrinsically labeled 57Fe)
Number of subjects: 21
Study: 36101477

Group type: EXPERIMENTAL
Intervention: Severe periodontitis
Number of subjects: 167

Group type: COMPARATOR
Intervention: None/mild periodontitis
Number of subjects: 167
Study: 36101502

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET) parameters
Number of subjects: 72
Study: 36101518

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA) and immune phenotyping
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Immune/inflammatory biomarkers
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: D-dimer
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Lp-PLA2, MCP-1, and oxLDL
Number of subjects: 755
Study: 36101520

Group type: EXPERIMENTAL
Intervention: Entrectinib-resistant ROS1+ NSCLC patients (CUTO28-ER cells)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Entrectinib-resistant ROS1+ NSCLC patients (STARTRK-2 trial)
Number of subjects: 105

Group type: COMPARATOR
Intervention: ROS1-selective inhibitors
Number of subjects: 105
Study: 36101543

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 14
Study: 36101656

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 10 mg orally
Number of subjects: 97

Group type: COMPARATOR
Intervention: Healthy control (HC) subjects
Number of subjects: 97
Study: 36102063

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36102232

Group type: EXPERIMENTAL
Intervention: Large LAA orifice group
Number of subjects: 302

Group type: COMPARATOR
Intervention: Small LAA orifice group
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 302
Study: 36102499

Group type: EXPERIMENTAL
Intervention: Creation of the Canadian Consortium for Research in Pediatric Surgery
Number of subjects: 0
Study: 36102523

Group type: EXPERIMENTAL
Intervention: P4HB Mesh (Phasix Mesh)
Number of subjects: 121
Study: 36102593

Group type: EXPERIMENTAL
Intervention: Virtual Reality Therapy (VRT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 42
Study: 36102707

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36102758

Group type: EXPERIMENTAL
Intervention: Ibrutinib, rituximab, and lenalidomide (iR2) regimen
Number of subjects: 30
Study: 36103041

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 259
Study: 36103259

Group type: EXPERIMENTAL
Intervention: Rolling Circle Amplification (RCA) testing
Number of subjects: 2205
Study: 36103292

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (sac/val)
Number of subjects: 130
Study: 36103365

Group type: EXPERIMENTAL
Intervention: Cleansing with tap water
Number of subjects: 2504

Group type: EXPERIMENTAL
Intervention: Cleansing with distilled water
Number of subjects: 2504

Group type: EXPERIMENTAL
Intervention: Cleansing with cooled boiled water
Number of subjects: 2504
Study: 36103643

Group type: EXPERIMENTAL
Intervention: MTB-directed therapy (both on-label and off-label therapies)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: MTB-directed therapy
Number of subjects: 93
Study: 36103646

Group type: EXPERIMENTAL
Intervention: Germline testing combined with tumor-only sequencing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tumor-only sequencing
Number of subjects: 100
Study: 36103903

Group type: EXPERIMENTAL
Intervention: Muscle strength improvement over time
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Physical performance improvement over time
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Musculoskeletal symptoms improvement over time
Number of subjects: 76
Study: 36104084

Group type: EXPERIMENTAL
Intervention: Learning collaborative educational bundle (learning sessions, communication skills training, implementation support)
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Learning collaborative educational bundle
Number of subjects: 1395
Study: 36104165

Group type: EXPERIMENTAL
Intervention: Individualised nasal continuous positive airway pressure (CPAP) level selection
Number of subjects: 12
Study: 36104359

Group type: EXPERIMENTAL
Intervention: camrelizumab (200 mg, q2w) and apatinib (250 mg, once daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: camrelizumab and apatinib
Number of subjects: 20
Study: 36104734

Group type: EXPERIMENTAL
Intervention: Fasting state
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Postprandial state (3 hours after consuming a fat-containing meal)
Number of subjects: 349
Study: 36104795

Group type: EXPERIMENTAL
Intervention: Elraglusib (9-ING-41) as a single agent
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Elraglusib (9-ING-41) in combination with anti-PD-1 mAb
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Sequential therapy with elraglusib and anti-PD-1 mAb
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control group (anti-PD-1 mAb)
Number of subjects: 1
Study: 36104949

Group type: EXPERIMENTAL
Intervention: Combination of anti-PD1/PD-L1 and dendritic cell (DC) therapy
Number of subjects: 9

Group type: COMPARATOR
Intervention: Combination therapy in mice
Number of subjects: 9
Study: 36104953

Group type: EXPERIMENTAL
Intervention: Stratified proportional win-fractions model
Number of subjects: 0
Study: 36105041

Group type: EXPERIMENTAL
Intervention: 3L-PEG
Number of subjects: 330

Group type: COMPARATOR
Intervention: 4L-PEG
Number of subjects: 330
Study: 36105230

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 36105269

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Number of subjects: 0
Study: 36105300

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle strength training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care aerobic exercise
Number of subjects: 0
Study: 36105799

Group type: EXPERIMENTAL
Intervention: ssCAR-T-19 cells (anti-CD19 CAR-T cells with shRNA targeting IL-6)
Number of subjects: 61
Study: 36105914

Group type: EXPERIMENTAL
Intervention: Ruxolitinib at the maximum safe starting dose (MSSD) of 10 mg bid
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 69
Study: 36105925

Group type: EXPERIMENTAL
Intervention: Remotely controlled mandibular positioner (RCMP) titration during in-lab sleep study
Number of subjects: 141
Study: 36106308

Group type: EXPERIMENTAL
Intervention: No-charge coronary artery calcium screening
Number of subjects: 36356
Study: 36106638

Group type: EXPERIMENTAL
Intervention: [11C]-TMP
Number of subjects: 0
Study: 36106847

Group type: EXPERIMENTAL
Intervention: CDED + PEN
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: EEN
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CDED + PEN or EEN
Number of subjects: 54
Study: 36107167

Group type: COMPARATOR
Intervention: Observational study
Number of subjects: 363
Study: 36107220

Group type: EXPERIMENTAL
Intervention: Famitinib 25 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Rifampin 600 mg
Number of subjects: 21
Study: 36107221

Group type: EXPERIMENTAL
Intervention: BCMA-CART cell therapy
Number of subjects: 4
Study: 36107363

Group type: EXPERIMENTAL
Intervention: Prophylactic beta-blockers
Number of subjects: 249
Study: 36107394

Group type: EXPERIMENTAL
Intervention: Zandelisib (45 or 60 mg daily)
Number of subjects: 9
Study: 36107411

Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 222

Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 222
Study: 36107473

Group type: EXPERIMENTAL
Intervention: mHealth intervention to support physical activity (PA)
Number of subjects: 10
Study: 36107482

Group type: EXPERIMENTAL
Intervention: CONEMO digital intervention (18-session psychoeducational program delivered via smartphone app)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: CONEMO digital intervention
Number of subjects: 217
Study: 36107483

Group type: EXPERIMENTAL
Intervention: Systemic treatment based on genetic analyses of tumor tissue
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Electronic patient-reported outcomes (PROs) via dedicated app
Number of subjects: 30
Study: 36107585

Group type: EXPERIMENTAL
Intervention: Supplementation manipulation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Draining manipulation
Number of subjects: 10
Study: 36107703

Group type: EXPERIMENTAL
Intervention: Maternal fecal microbiome
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Infant fecal microbiome
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Longitudinal gut microenvironment profile
Number of subjects: 657

Group type: COMPARATOR
Intervention: Cesarean section
Number of subjects: 657
Study: 36107810

Group type: EXPERIMENTAL
Intervention: Newborn screening programs for congenital hypothyroidism
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Genetic work-up for congenital hypothyroidism
Number of subjects: 2
Study: 36108135

Group type: EXPERIMENTAL
Intervention: Combined rehabilitation program (home-based respiratory physiotherapy and telephone-based psychological support) consisting of 12 at-home respiratory rehabilitation sessions and 6 telephone-based psychological sessions.
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual posthospital care provided by a public Peruvian hospital.
Number of subjects: 108
Study: 36108144

Group type: EXPERIMENTAL
Intervention: Bronchial remodeling-based latent class analysis
Number of subjects: 0
Study: 36108254

Group type: EXPERIMENTAL
Intervention: Community-based participatory approach to expand sustainable COVID-19 testing capacity
Number of subjects: 0
Study: 36108256

Group type: EXPERIMENTAL
Intervention: In-home rapid antigen COVID-19 testing (BinaxNOW), administered twice weekly for three months.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symptomatic testing during the in-home testing program.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-home testing program participants opting for symptom testing.
Number of subjects: 0
Study: 36108259

Group type: EXPERIMENTAL
Intervention: 80-gene assay (genomic classification)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Dual HER2-targeted therapy (trastuzumab plus pertuzumab)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Standard-of-care neoadjuvant chemotherapy with trastuzumab
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: 80-gene assay
Number of subjects: 295
Study: 36108304

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) JZP458 25/25/50 mg/m2 MWF
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) JZP458 25 mg/m2 MWF
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) JZP458 37.5 mg/m2 MWF
Number of subjects: 167
Study: 36108308

Group type: EXPERIMENTAL
Intervention: Rondaptivon pegol (3 mg on days 0 and 4, then weekly doses of 2 to 9 mg until day 28)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Rondaptivon pegol (6 doses)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Rondaptivon pegol
Number of subjects: 19
Study: 36108310

Group type: EXPERIMENTAL
Intervention: Dexcom G4 CGM
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Abbott Libre Pro CGM
Number of subjects: 186
Study: 36108334

Group type: EXPERIMENTAL
Intervention: MoveStrong exercise and nutrition program (8-week duration, with 4-week follow-up), including personalized exercise program, 11 remote training sessions, and 3 nutrition education sessions.
Number of subjects: 30
Study: 36108341

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 55
Study: 36108425

Group type: EXPERIMENTAL
Intervention: Isatuximab plus pomalidomide and dexamethasone (Isa-Pd)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Isatuximab plus carfilzomib and dexamethasone (Isa-Kd)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (pomalidomide and dexamethasone or carfilzomib and dexamethasone)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Isatuximab (Isa)
Number of subjects: 2
Study: 36108560

Group type: EXPERIMENTAL
Intervention: BI 836880 (40-1000 mg Q3W)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: BI 836880 (40-240 mg QW)
Number of subjects: 53